Humulin S (Soluble) (Insulin Human)

Humulin S (Soluble) is indicated for the management of blood glucose in adults and children with diabetes.

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus
• Basal‑bolus insulin regimens combined with longer‑acting insulins
• Correction of post‑prandial hyperglycemia
• Intravenous insulin infusion in hospital settings
• Use during pregnancy when insulin therapy is required, following specialist guidance

• Humulin S contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production. The rapid onset and short duration of action reflect the soluble formulation’s quick absorption after subcutaneous injection.

Adverse reactions to Humulin S may occur; they are categorized by frequency and severity.

Common

• Hypoglycemia (low blood glucose)
• Injection‑site pain or bruising
• Lipodystrophy at the injection site
• Weight gain
• Mild skin rash or itching

Serious

• Severe hypoglycemia with loss of consciousness or seizures
• Anaphylactic or severe allergic reaction
• Hypokalemia (low potassium levels)
• Pulmonary edema or fluid retention
• Bronchospasm associated with hypersensitivity

Before using Humulin S, consider the following safety measures.

• Regularly monitor blood glucose and adjust dose as needed
• Adjust dosing during illness, pregnancy, or renal/hepatic impairment
• Avoid use in patients with known hypersensitivity to human insulin
• Use cautiously in individuals with cardiovascular disease
• Educate patients on recognizing and treating hypoglycemia
• Store the product in a refrigerator and protect from light
• Do not mix with other insulins unless compatibility is confirmed

Humulin S can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Simultaneous use of other rapid‑acting insulins without dose adjustment
• Unsupervised combination with GLP‑1 receptor agonists that may increase hypoglycemia risk

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms
• Thiazide diuretics, which may raise blood glucose levels
• Corticosteroids, which can increase insulin requirements
• ACE inhibitors or ARBs, which may potentiate hypoglycemia
• Alcohol consumption, which can potentiate insulin’s glucose‑lowering effect